Quanterix Corporation Payments to Acquire Marketable Securities
Quanterix Corporation (QTRX) reported Payments to Acquire Marketable Securities of $8.24 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-10
- Quanterix Corporation payments to acquire marketable securities for the quarter ending 2026-06-30 was $8.24M.
- Quanterix Corporation payments to acquire marketable securities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Quanterix Corporation payments to acquire marketable securities for the quarter ending 2025-12-31 was $24.10M, a 2.17% decline year-over-year.
- Quanterix Corporation payments to acquire marketable securities for the quarter ending 2025-09-30 was $15.41M, a 81.12% decline year-over-year.
- Quanterix Corporation payments to acquire marketable securities for fiscal 2025 was $69.76M, a 76.40% decline from fiscal 2024.
- Quanterix Corporation payments to acquire marketable securities for fiscal 2024 was $295.61M, a 68.33% increase from fiscal 2023.
- Quanterix Corporation payments to acquire marketable securities for fiscal 2023 was $175.61M.
- Quanterix Corporation payments to acquire marketable securities for fiscal 2022 was $0.00.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $8.24M 10-Q · filed 2026-08-10 | $32.34M derived: sum of 3 quarters · filed 2026-08-10 | $47.76M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-06 | $24.10M derived: sum of 2 quarters · filed 2026-05-06 | $39.51M derived: sum of 3 quarters · filed 2026-05-06 | $39.51M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $24.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $39.51M derived: sum of 2 quarters · filed 2026-03-02 | $39.51M derived: sum of 3 quarters · filed 2026-08-10 | $69.76M 10-K · filed 2026-03-02 |
| 2025-09-30 | $15.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $15.41M derived: sum of 2 quarters · filed 2026-08-10 | $45.66M 10-Q · filed 2025-11-10 | $70.29M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $30.25M 10-Q · filed 2026-08-10 | $54.88M derived: sum of 3 quarters · filed 2026-08-10 | $136.51M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $30.25M 10-Q · filed 2026-05-06 | $54.88M derived: sum of 2 quarters · filed 2026-05-06 | $136.51M derived: sum of 3 quarters · filed 2026-05-06 | $187.96M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $24.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $106.26M derived: sum of 2 quarters · filed 2026-03-02 | $157.72M derived: sum of 3 quarters · filed 2026-03-02 | $295.61M 10-K · filed 2026-03-02 |
| 2024-09-30 | $81.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $133.08M derived: sum of 2 quarters · filed 2025-11-10 | $270.97M 10-Q · filed 2025-11-10 | $321.38M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $51.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $189.34M 10-Q · filed 2025-08-07 | $239.76M derived: sum of 3 quarters · filed 2026-03-02 | $364.96M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $137.89M 10-Q · filed 2025-05-12 | $188.30M derived: sum of 2 quarters · filed 2026-03-02 | $313.50M derived: sum of 3 quarters · filed 2026-03-02 | $313.50M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $50.41M derived: 10-K 12 month − 10-K/A 9 month · filed 2026-03-02 | $175.61M derived: sum of 2 quarters · filed 2026-03-02 | $175.61M derived: sum of 3 quarters · filed 2026-03-02 | $175.61M 10-K · filed 2026-03-02 |
| 2023-09-30 | $125.20M derived: 10-K/A 9 month − 10-Q/A 6 month · filed 2024-12-26 | $125.20M derived: sum of 2 quarters · filed 2024-12-26 | $125.20M 10-K/A · filed 2024-12-26 | |
| 2023-06-30 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-12-26 | $0.00 10-Q/A · filed 2024-12-26 | ||
| 2023-03-31 | $0.00 10-Q/A · filed 2024-12-26 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-17 | |||
| 2021-12-31 | $0.00 10-K/A · filed 2024-12-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nautilus Biotechnology, Inc. (NAUT) | United States | $0.129B | -4.16 |
| Seer, Inc. (SEER) | United States | $0.104B | -1.34 |
| Precipio, Inc. (PRPO) | United States | $0.043B | -36.70 |
| HARVARD BIOSCIENCE INC (HBIO) | United States | $0.037B | -2.70 |
| Bionano Genomics, Inc. (BNGO) | United States | $0.020B | -0.42 |
| ASTROTECH Corp (ASTC) | United States | $0.013B | |
| EyePoint, Inc. (EYPT) | United States | $0.314B | -3.96 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |